The price of Invega Sustenna (paliperidone palmitate extended-release injectable suspension) can vary significantly based on factors such as insurance coverage, pharmacy, and geographic location.
How much does Invega Sustenna cost without insurance?
Without insurance, the retail price for a 3-month supply of Invega Sustenna can range from approximately $3,500 to over $4,000 [1]. For a single 3.5 mL (100 mg) vial, the cost can be around $1,200 to $1,500 [1]. These prices are estimates and can fluctuate.
Can I get financial assistance for Invega Sustenna?
Pharmaceutical manufacturers often offer patient assistance programs to help reduce out-of-pocket costs for eligible individuals. For Invega Sustenna, the manufacturer, Janssen, provides a program called Janssen CarePath [2]. This program may offer co-pay assistance cards for commercially insured patients, potentially lowering their costs to as little as $0 per month for up to 24 months [2]. Eligibility criteria and program details can vary.
What are the typical co-pays for Invega Sustenna with insurance?
With commercial insurance, co-pay costs for Invega Sustenna can also vary widely. Some assistance programs may reduce these co-pays to a nominal amount, such as $10 or $20 per prescription [2]. However, without such programs or with certain insurance plans, co-pays could be substantially higher. Medicare and Medicaid coverage for Invega Sustenna also depends on the specific plan details and may involve different co-payment structures.
How does Invega cost compare to other long-acting antipsychotics?
Other long-acting injectable antipsychotics also have varying price points. For example, Abilify MyCite (aripiprazole) and Aristada (aripiprazole lauroxil) are also long-acting options, and their costs can be comparable to or different from Invega Sustenna depending on the specific formulation and dosage. The overall cost-effectiveness of these treatments also involves factors beyond the drug price, such as hospitalization rates and adherence to therapy.
When does the patent for Invega Sustenna expire?
The patent landscape for Invega Sustenna is complex, with multiple patents covering the drug and its formulations. According to DrugPatentWatch.com, the earliest patent for paliperidone palmitate expired in September 2023 [3]. However, other patents may extend market exclusivity for specific formulations or indications. The expiration of these patents could pave the way for generic versions of paliperidone palmitate long-acting injectables.
Sources:
[1] GoodRx. Invega Sustenna Prices, Coupons, and Patient Assistance Programs. https://www.goodrx.com/invega-sustenna
[2] Janssen. Janssen CarePath. https://www.janssen.com/patients/janssen-carepath
[3] DrugPatentWatch. Paliperidone Palmitate. https://drugpatentwatch.com/paliperidone-palmitate